BAY AREA, July 13, 2016 /PRNewswire/ —
The worldwide next-generation sequencing marketplace is expected to achieve USD 14.0 million by 2024, based on a brand new statement by Grand View Study, Inc. Developing ownership of next-generation sequencing approaches for diagnosis and therapy tabs on various serious illnesses for example cancer along with other pathogenic attacks is among the high-impact manifestation driver for improvement within this business.
Software of genome and exome sequencing within the area of cancer study for friend diagnostics and biomarker development are required to lead towards the development of the marketplace through the outlook time.
Furthermore, expected exponential reduction in the costs of sequence dedication along with the start of whole-genome sequencers and book systems by main industry people is likely to possess a substantial beneficial effect on numerous NGS applications’ market penetration.
Search complete research statement with TOC on “Nextgeneration Sequencing (NGS) Market Investigation by Software (HLA Screening, Prenatal Screening, Oncology, Idiopathic & Infectious Diseases), By Engineering (Total Genome Sequencing, Entire Exon Sequencing, Specific Sequencing & Resequencing), By Workflow (NGS Pre-Sequencing, NGS Sequencing, NGS Main, Extra & Tertiary Data Analysis), By Stop-use (Educational, Medical Study, Hospitals & Centers, Pharma & Biotech